On Monday, Shares of Old Republic International Corporation (NYSE:ORI), lost -0.06% to $16.09.
Old Republic International Corporation, declared that it will hold a conference call on Thursday, July 23, at 3:00 p.m. Eastern Time to talk about second quarter 2015 results. The call can be accessed live on Old Republic’s website at www.oldrepublic.com, or on a listen-only phone line at 888-576-4398.
Old Republic International Corporation, through its auxiliaries, engages in the insurance underwriting and related services business primarily in the United States and Canada.
Shares of Cowen Group Inc (NASDAQ:COWN), declined -7.66% to $6.03, during its last trading session.
Cowen Group, declared that George Mihalos has joined Cowen and Company’s Equity Research department as a Director to cover payments and financial information stocks. Mr. Mihalos is based in New York and reports to Robert Fagin, Cowen’s Director of Research.
“The pace of innovation and disruption in the payments industry necessitates expert analysis,” said Mr. Fagin. “George’s depth of knowledge will assist investors navigate this complex sector.”
Cowen Group, Inc. is a publicly owned asset administration holding company. Through its auxiliaries, the firm provides alternative investment administration, investment banking, research, and sales and trading services for its clients. It manages separate client focused portfolio through its auxiliaries.
At the end of Monday’s trade, Shares of Cablevision Systems Corporation (NYSE:CVC), lost -2.17% to $26.56.
Cablevision Systems Corporation, will host a conference call to talk about results for the second quarter ended June 30, 2015 on Friday, August 7, 2015 at 10:00 a.m. Eastern Time. Cablevision will issue a press release reporting its results preceding to the market opening.
Cablevision Systems Corporation, together with its auxiliaries, owns and operates cable systems in the United States. The company operates through three segments: Cable, Lightpath, and Other.
Finally, CorMedix Inc. (NYSEMKT:CRMD), ended its last trade with -23.76% loss, and closed at $3.24.
CorMedix, declared an update to its formerly declared planned transaction process and that it anticipates to initiate the first Phase 3 study for its lead product Neutrolin(R) in the fourth quarter, 2015.
The Phase 3 clinical trial is designed to be a U.S. multi-center, randomized, controlled study comparing Neutrolin to heparin in an estimated 633 patients in hemodialysis being monitored for catheter related bloodstream infections (CRBSI). Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will serve as the Study Chair.
CorMedix Inc., a pharmaceutical company, intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
